Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd Live Price Chart
Performance
| Previous Close | ₹ 8.08 |
| High | ₹ 8.48 |
| Volume | 10755 |
| 52W Range | ₹ 5 - ₹ 10.32 |
| Open | ₹ 8.12 |
| Low | ₹ 8.12 |
| Market Cap | ₹ 6 Cr |
Hindustan Bio Sciences Ltd Technicals
| 20 Day | ₹ 7.815 |
| 50 Day | ₹ 7.567 |
| 100 Day | ₹ 7.391 |
| 200 Day | ₹ 7.570 |
| 20 Day | ₹ 7.747 |
| 50 Day | ₹ 7.668 |
| 100 Day | ₹ 6.879 |
| 200 Day | ₹ 7.641 |
Hindustan Bio Sciences Ltd Fundamentals
| ROCE | 0.667 |
| P/E Ratio | 60.570 |
| P/B Ratio | 10.100 |
| Industry P/E | 10.100 |
| Debt to Equity | 39.020 |
| ROE | 2.557 |
| EPS | 0.140 |
| Dividend Yield | 0.000 |
| Book Value | 0.839 |
| Face Value | 2.000 |
Hindustan Bio Sciences Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 0.8133 | 1.0528 | 0.9223208 | 0.430612 | 1.0319225 |
| Total Expenses | 0.7151 | 0.9995 | 0.96027 | 0.9451056 | 1.987259 |
| Profit After Tax | 0.1007 | 0.0576 | -0.0404531 | -0.5175433 | -0.9398485 |
Hindustan Bio Sciences Ltd Shareholding Pattern
| Promoter Holdings | 12.190 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 81.690 % |
| Others - | 6.120 % |
About Hindustan Bio Sciences Ltd
Hindustan Bio Science Limited was initially incorporated as Garuda Cements Limited in December 1991. Earlier, it was engaged in cement manufacturing and due to sluggish in the industry, the Company diversified its business into Bio Technology & Pharmaceuticals activities in 2000-01 and the name was changed from Garuda Cements Limited to Hindustan Bio-Sciences Limited. In 2002, it diversified into software field and subsequently changed its name to Hindustan Bio Sciences Limited on August 8, 2002. The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified businesses in pharmaceutical and biotechnology industries. The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates. It acquired the shares of Venkar Chemicals Ltd in 2004 and upon the acquisition, it became Wholly owned subsidiary of the Company with effect from 19.08.2004. During 2006-07, Company got approval from Drugs Controller General of India (DCGI) and started marketing the nephrology product 'Recombinant Human Erythropoietin' with the brand name 'EPOVIN' from June, 2007. The Company operate its manufacturing plants for dry and liquid injectables, liquid/dry syrups, Eye/Ear/Nasal drops, pre-filled syringes and non sterile/sterile ointments, tablets and capsules approved by several regulatory authorities and is trusted by healthcare profe ...
